RNA
Therapeutics Market (technology, applications, end user and geography) -
Industry Analysis and Forecast, 2013 - 2020 report suggests that the RNA Based
Therapeutics Market would reach $1.2 billion by 2020 registering a CAGR of
28.4% during 2014 - 2020. Due to its ability to render targeted solutions for
chronic diseases such as cancer, AIDS, rare genetic disorders, and certain
cardiovascular conditions, RNA based therapeutics is expected to significantly
impact the global pharmaceutical industry.
The
large scale funding from public and private sector, growing interest of
pharmaceuticals and biotech giants for developing novel delivery technology,
and anticipated saving in healthcare expenditure are propelling the growth of
RNA therapeutics market. Moreover, the platform technologies such as RNAi and
antisense have enabled researchers to accelerate their research activities by
defining gene sequences for chronic diseases. Companies have widened the
research focus on RNA based drug as well, which has fueled the growth of the
overall RNA therapeutics market.Pharmaceutical companies have identified the
RNA therapeutics for variety of chronic diseases and are also exploring the
potential of RNA technology for diagnostic purposes. The RNA based therapeutics
market, in the near future is likely to witness a substantial level of momentum
due to government funding and programs aimed at commercialization of these
drugs. The government of United States, through its National Institute of
Health (NIH), provides funds for RNA therapeutics research, thus assist in
propelling the growth of this market. To boost the research activities the U.S.
FDA is providing fast track designation to the RNA products, which are in the
pipeline.
The
study suggests that the enabled technologies such as RNA interference
technology (RNAi) and RNA antisense technology will dominate the market with
RNAi technology getting interest from most of the participants. The development
pipeline suggests that oncology segment will emerge as the largest application
segment. This is largely due to the high prevalence of such diseases and
limited efficiency of available therapeutics in treating such diseases.
Research and therapeutics are the two major end-use segments for RNA
therapeutics market. North America currently commands the lion's share of the
market as most of the research and development activity is concentrated in this
region. However, Asia Pacific and other emerging regions will gradually
catch-up over the forecast period.
The
Key companies in this space are Alnylam Pharmaceuticals, Inc., Benitec
Biopharma Limited, Cenix BioScience GmbH, Dicerna Pharmaceuticals, Inc.,
Genzyme Corporation, ISIS pharmaceuticals Inc., Quark Pharmaceuticals, Inc.,
Silence Therapeutics PLC, and Tekmira Pharmaceuticals Corp. These organizations
have raised funds from private and public sectors to bear the high cost of RNA
therapeutics research. Though the clinical results behind RNA based
therapeutics are compelling, the Pharma and biotech companies are still working
to identify opportunistic areas to grow. It is most likely that the RNA
therapeutic companies would successfully tackle the drug delivery issue, which
is the major hurdle in commercialization of this therapeutics and at the same
time would reap benefits.
Spanning
over 140 pages, “Global RNA Based
Therapeutics Market (Technology, Application, End Users and Geography) - Size,
Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research,
Report, Opportunities, Segmentation and Forecast, 2013 - 2020” report
covering the Introduction, Executive Summary, Market Overview, Global RNA Based
Therapeutics Market By Technologies,
2013-2020, $Million, Global RNA Based Therapeutics Market By Applications,
2013-2020, $Million, Global RNA Based Therapeutics Market By End Users,
2013-2020, $Million, Global RNA Based Therapeutics Market By Geography,
2013-2020, $Million, Company Profiles. The report covered companies are - Quark
Pharmaceuticals, Inc. (USA), Alnylam
Pharmaceuticals, Inc. (USA), Dicerna Pharmaceuticals, Inc. (USA), Tekmira
Pharmaceuticals Corp. (Canada), Benitec Biopharma Limited (Australia), Cenix
BioScience GmbH (Germany), Genzyme Corporation (USA) (A Sanofi Company),
Silence Therapeutics PLC (UK), Sirnaomics, Inc. (USA)
Know more about this report
at
– http://mrr.cm/Zz2
Find
all Therapeutic Reports at: http://www.marketresearchreports.com/therapeutic
No comments:
Post a Comment
Note: only a member of this blog may post a comment.